Y Intercept Hong Kong Ltd Increases Stake in Humana Inc. (NYSE:HUM)

Y Intercept Hong Kong Ltd raised its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 180.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 5,741 shares of the insurance provider's stock after purchasing an additional 3,696 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Humana were worth $1,818,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. MML Investors Services LLC raised its stake in Humana by 15.6% during the third quarter. MML Investors Services LLC now owns 4,737 shares of the insurance provider's stock worth $1,500,000 after buying an additional 638 shares during the last quarter. XTX Topco Ltd acquired a new stake in Humana during the 3rd quarter worth about $1,727,000. National Bank of Canada FI raised its position in shares of Humana by 54.4% in the 3rd quarter. National Bank of Canada FI now owns 83,987 shares of the insurance provider's stock worth $26,602,000 after acquiring an additional 29,593 shares in the last quarter. Insigneo Advisory Services LLC lifted its stake in shares of Humana by 14.2% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,159 shares of the insurance provider's stock valued at $367,000 after purchasing an additional 144 shares during the period. Finally, Kovitz Investment Group Partners LLC boosted its position in shares of Humana by 61.6% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 4,179 shares of the insurance provider's stock valued at $1,324,000 after purchasing an additional 1,593 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of HUM stock traded down $7.79 during trading on Wednesday, hitting $278.03. The company's stock had a trading volume of 1,812,242 shares, compared to its average volume of 1,844,360. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.48 billion, a PE ratio of 24.64, a P/E/G ratio of 2.18 and a beta of 0.53. The business has a fifty day moving average of $272.20 and a 200-day moving average of $325.92. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $488.89.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, research analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.27%. The ex-dividend date is Tuesday, December 31st. Humana's dividend payout ratio is 31.36%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HUM. Truist Financial dropped their price target on Humana from $400.00 to $260.00 and set a "hold" rating on the stock in a research note on Friday, October 11th. Leerink Partners lowered shares of Humana from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. lifted their price target on shares of Humana from $332.00 to $396.00 and gave the company a "neutral" rating in a research note on Wednesday, August 21st. KeyCorp began coverage on shares of Humana in a research report on Friday, October 11th. They set a "sector weight" rating on the stock. Finally, Royal Bank of Canada decreased their target price on Humana from $400.00 to $265.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Humana presently has a consensus rating of "Hold" and a consensus target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.